Advisory Services Network’s Enliven Therapeutics ELVN Stock Holding History

Advisory Services Network’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$41	–	2516
2025 Q3	$41	Buy	+2	New	+$40	﹤0.01%	4474
2021 Q4	–	Sell	-2,920	Closed	-$48K	–	1424
2021 Q3	$48K	Sell	2,920 -250	-8%	-$5.19K	﹤0.01%	1360
2021 Q2	$100K	Buy	3,170 +250	+9%	+$7.75K	﹤0.01%	1615
2021 Q1	$99K	Buy	+2,920	New	+$148K	﹤0.01%	1246

Other funds holding ELVN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Advisory Services Network's ELVN Position: Q4 2025 in Review

Advisory Services Network sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 2 shares — an estimated $41 sold.

Advisory Services Network first reported a position in ELVN in Q1 2021 and held it in 4 quarters. The position peaked at $100K in Q2 2021. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

Advisory Services Network reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
Advisory Services Network sold 2 Enliven Therapeutics shares in Q4 2025, an estimated $41.
Advisory Services Network first reported a position in Enliven Therapeutics in Q1 2021 and held it in 4 quarters.
Advisory Services Network's Enliven Therapeutics position peaked at $100K in Q2 2021.
125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Advisory Services Network's 13F filing for Q4 2025, filed 17 Feb 2026.